AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
Log in

LON:AGLANGLE Share Price, Forecast & News

GBX 63.50
+2.00 (+3.25 %)
(As of 05/27/2020 01:00 AM ET)
Add
Compare
Today's Range
60.63
Now: GBX 63.50
64
50-Day Range
49
MA: GBX 59.83
68.50
52-Week Range
40
Now: GBX 63.50
85
Volume73,052 shs
Average Volume106,228 shs
Market Capitalization£109.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests rare circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application and others. The company was founded in 2004 and is based in Guildford, the United Kingdom.
Read More
ANGLE logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.57 out of 5 stars


Industry, Sector and Symbol

Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1483-685830

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£806,000.00
Cash FlowGBX 12.28 per share
Book ValueGBX 18 per share

Profitability

Miscellaneous

Employees43
Market Cap£109.73 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AGL News and Ratings via Email

Sign-up to receive the latest news and ratings for AGL and its competitors with MarketBeat's FREE daily newsletter.

ANGLE (LON:AGL) Frequently Asked Questions

How has ANGLE's stock been impacted by COVID-19 (Coronavirus)?

ANGLE's stock was trading at GBX 65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGL stock has decreased by 2.3% and is now trading at GBX 63.50. View which stocks have been most impacted by Coronavirus.

How were ANGLE's earnings last quarter?

ANGLE plc (LON:AGL) released its earnings results on Thursday, January, 30th. The company reported ($3.33) EPS for the quarter. View ANGLE's earnings history.

Has ANGLE been receiving favorable news coverage?

News stories about AGL stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ANGLE earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutANGLE.

Who are some of ANGLE's key competitors?

What other stocks do shareholders of ANGLE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANGLE investors own include Yamana Gold (YRI), Asiamet Resources (ARS), Dekeloil Public (DKL), Eldorado Gold (ELD), Polo Resources (POL), Silvercorp Metals (SVM), First Majestic Silver (AG), African Potash (AFPO), Ariana Resources (AAU) and Alamos Gold (AGI).

Who are ANGLE's key executives?

ANGLE's management team includes the following people:
  • Mr. Andrew David William Newland, Founder, CEO & Exec. Director (Age 57)
  • Mr. Ian Francis Griffiths, CFO, Fin. Director, Company Sec. & Exec. Director (Age 54)
  • Dr. Daniel J. O'Shannessy, Chief Scientific Officer
  • Mr. Paul Smith, VP & Chief Exec. Officer of ANGLE Biosciences Inc
  • Mr. Martin Cooke, Director of Manufacturing & Regulatory Affairs (Age 50)

What is ANGLE's stock symbol?

ANGLE trades on the London Stock Exchange (LON) under the ticker symbol "AGL."

How do I buy shares of ANGLE?

Shares of AGL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ANGLE's stock price today?

One share of AGL stock can currently be purchased for approximately GBX 63.50.

How big of a company is ANGLE?

ANGLE has a market capitalization of £109.73 million and generates £806,000.00 in revenue each year. ANGLE employs 43 workers across the globe.

What is ANGLE's official website?

The official website for ANGLE is www.angleplc.com.

How can I contact ANGLE?

ANGLE's mailing address is The Surrey Research Park 3 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company can be reached via phone at +44-1483-685830.

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.